Liver Fibrosis Regression Measured by Transient Elastography in Human Immunodeficiency Virus (HIV)-Hepatitis B Virus (HBV)-Coinfected Individuals on Long-Term HBV-Active Combination Antiretroviral Therapy

Overview

Journal Open Forum Infect Dis

Specialty Infectious Diseases

Date 2016 Mar 24

PMID 27006960

Citations 11

Authors

Jennifer Audsley

Christopher Robson

Stacey Aitchison

Gail V Matthews

David Iser

Joe Sasadeusz

Sharon R Lewin

Affiliations

Soon will be listed here.

Abstract

Background. Advanced fibrosis occurs more commonly in human immunodeficiency virus (HIV)-hepatitis B virus (HBV) coinfected individuals; therefore, fibrosis monitoring is important in this population. However, transient elastography (TE) data in HIV-HBV coinfection are lacking. We aimed to assess liver fibrosis using TE in a cross-sectional study of HIV-HBV coinfected individuals receiving combination HBV-active (lamivudine and/or tenofovir/tenofovir-emtricitabine) antiretroviral therapy, identify factors associated with advanced fibrosis, and examine change in fibrosis in those with >1 TE assessment. Methods. We assessed liver fibrosis in 70 HIV-HBV coinfected individuals on HBV-active combination antiretroviral therapy (cART). Change in fibrosis over time was examined in a subset with more than 1 TE result (n = 49). Clinical and laboratory variables at the time of the first TE were collected, and associations with advanced fibrosis (≥F3, Metavir scoring system) and fibrosis regression (of least 1 stage) were examined. Results. The majority of the cohort (64%) had mild to moderate fibrosis at the time of the first TE, and we identified alanine transaminase, platelets, and detectable HIV ribonucleic acid as associated with advanced liver fibrosis. Alanine transaminase and platelets remained independently advanced in multivariate modeling. More than 28% of those with >1 TE subsequently showed liver fibrosis regression, and higher baseline HBV deoxyribonucleic acid was associated with regression. Prevalence of advanced fibrosis (≥F3) decreased 12.3% (32.7%-20.4%) over a median of 31 months. Conclusions. The observed fibrosis regression in this group supports the beneficial effects of cART on liver stiffness. It would be important to study a larger group of individuals with more advanced fibrosis to more definitively assess factors associated with liver fibrosis regression.

Citing Articles

HIV-HBV Coinfection-Current Challenges for Virologic Monitoring.

Ruta S, Grecu L, Iacob D, Cernescu C, Sultana C Biomedicines. 2023; 11(5).

PMID: 37238976 PMC: 10215721. DOI: 10.3390/biomedicines11051306.

Long-term trends of alanine aminotransferase levels among persons living with human immunodeficiency virus/hepatitis B virus with and without hepatitis delta coinfection.

Begre L, Beguelin C, Boyd A, Peters L, Rockstroh J, Gunthard H Front Med (Lausanne). 2022; 9:988356.

PMID: 36186807 PMC: 9522477. DOI: 10.3389/fmed.2022.988356.

Liver fibrosis progression in a cohort of young HIV and HIV/ HBV co-infected patients: A longitudinal study using non-invasive APRI and Fib-4 scores.

Iacob D, Luminos M, Benea O, Tudor A, Olariu C, Iacob S Front Med (Lausanne). 2022; 9:888050.

PMID: 35966860 PMC: 9372617. DOI: 10.3389/fmed.2022.888050.

A Prospective Study Evaluating Changes in Histology, Clinical and Virologic Outcomes in HBV-HIV Co-infected Adults in North America.

Sterling R, King W, Khalili M, Chung R, Sulkowski M, Jain M Hepatology. 2021; 74(3):1174-1189.

PMID: 33743541 PMC: 8597319. DOI: 10.1002/hep.31823.

Characteristics and outcomes of antiretroviral-treated HIV-HBV co-infected patients in Canada?.

Rana U, Driedger M, Sereda P, Pan S, Ding E, Wong A BMC Infect Dis. 2019; 19(1):982.

PMID: 31752729 PMC: 6873547. DOI: 10.1186/s12879-019-4617-8.

References

Osakabe K, Ichino N, Nishikawa T, Sugiyama H, Kato M, Kitahara S . Reduction of liver stiffness by antiviral therapy in chronic hepatitis B. J Gastroenterol. 2011; 46(11):1324-34. DOI: 10.1007/s00535-011-0444-4. View

Martin-Carbonero L, Teixeira T, Poveda E, Plaza Z, Vispo E, Gonzalez-Lahoz J . Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on long-term nucleos(t)ide analogues. AIDS. 2010; 25(1):73-9. DOI: 10.1097/QAD.0b013e328340fde2. View

Piroth L, Pol S, Lacombe K, Miailhes P, Rami A, Rey D . Management and treatment of chronic hepatitis B virus infection in HIV positive and negative patients: the EPIB 2008 study. J Hepatol. 2010; 53(6):1006-12. DOI: 10.1016/j.jhep.2010.04.041. View

Audsley J, du Cros P, Goodman Z, McLean C, Mijch A, Lewin S . HIV replication is associated with increased severity of liver biopsy changes in HIV-HBV and HIV-HCV co-infection. J Med Virol. 2012; 84(7):993-1001. DOI: 10.1002/jmv.23236. View

Stockdale A, Phillips R, Beloukas A, Appiah L, Chadwick D, Bhagani S . Liver Fibrosis by Transient Elastography and Virologic Outcomes After Introduction of Tenofovir in Lamivudine-Experienced Adults With HIV and Hepatitis B Virus Coinfection in Ghana. Clin Infect Dis. 2015; 61(6):883-91. DOI: 10.1093/cid/civ421. View

Tapper E, Cohen E, Patel K, Bacon B, Gordon S, Lawitz E . Levels of alanine aminotransferase confound use of transient elastography to diagnose fibrosis in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol. 2012; 10(8):932-937.e1. PMC: 3402604. DOI: 10.1016/j.cgh.2012.01.015. View

Falade-Nwulia O, Seaberg E, Rinaldo C, Badri S, Witt M, Thio C . Comparative risk of liver-related mortality from chronic hepatitis B versus chronic hepatitis C virus infection. Clin Infect Dis. 2012; 55(4):507-13. PMC: 3520384. DOI: 10.1093/cid/cis432. View

Chan H, Wong G, Choi P, Chan A, Chim A, Yiu K . Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B. J Viral Hepat. 2008; 16(1):36-44. DOI: 10.1111/j.1365-2893.2008.01037.x. View

Brook M, Gilson R, Wilkins E . BHIVA Guidelines: coinfection with HIV and chronic hepatitis B virus. HIV Med. 2003; 4 Suppl 1:42-51. DOI: 10.1046/j.1468-1293.4.s1.1.x. View

10.

Fung J, Lai C, But D, Hsu A, Seto W, Cheng C . Reduction of liver stiffness following resolution of acute flares of chronic hepatitis B. Hepatol Int. 2011; 4(4):716-22. PMC: 2978896. DOI: 10.1007/s12072-010-9189-z. View

11.

Colin J, Cazals-Hatem D, Loriot M, Martinot-Peignoux M, Pham B, Auperin A . Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology. 1999; 29(4):1306-10. DOI: 10.1002/hep.510290447. View

12.

Yuen M, Chow D, Tsui K, Wong B, Yuen J, Wong D . Liver histology of Asian patients with chronic hepatitis B on prolonged lamivudine therapy. Aliment Pharmacol Ther. 2005; 21(7):841-9. DOI: 10.1111/j.1365-2036.2005.02410.x. View

13.

Lincoln D, Petoumenos K, Dore G . HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy. HIV Med. 2003; 4(3):241-9. DOI: 10.1046/j.1468-1293.2003.00152.x. View

14.

Sterling R, Lissen E, Clumeck N, Sola R, Correa M, Montaner J . Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006; 43(6):1317-25. DOI: 10.1002/hep.21178. View

15.

Soriano V, Puoti M, Bonacini M, Brook G, Cargnel A, Rockstroh J . Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. AIDS. 2005; 19(3):221-40. View

16.

Yan L, Zhu X, Bai L, Liang L, Chen E, Du L . Impact of mild to moderate elevations of alanine aminotransferase on liver stiffness measurement in chronic hepatitis B patients during antiviral therapy. Hepatol Res. 2012; 43(2):185-91. DOI: 10.1111/j.1872-034X.2012.01068.x. View

17.

SanMartin R, Tor J, Sanvisens A, Lopez J, Jou A, Muga R . Progression of liver fibrosis in HIV/hepatitis C virus-coinfected individuals on antiretroviral therapy with early stages of liver fibrosis at baseline. HIV Med. 2013; 15(4):203-12. DOI: 10.1111/hiv.12105. View

18.

Lacombe K, Bottero J, Lemoine M, Boyd A, Girard P . HIV/hepatitis B virus co-infection: current challenges and new strategies. J Antimicrob Chemother. 2009; 65(1):10-7. DOI: 10.1093/jac/dkp414. View

19.

Al-Mohri H, Murphy T, Lu Y, Lalonde R, Klein M . Evaluating liver fibrosis progression and the impact of antiretroviral therapy in HIV and hepatitis C coinfection using a noninvasive marker. J Acquir Immune Defic Syndr. 2007; 44(4):463-9. DOI: 10.1097/QAI.0b013e318030ff8e. View

20.

Thio C, Seaberg E, Skolasky Jr R, Phair J, Visscher B, Munoz A . HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet. 2002; 360(9349):1921-6. DOI: 10.1016/s0140-6736(02)11913-1. View